Yangshengtang

Yangshengtang has developed a novel monoclonal antibody targeting hepatitis B surface antigen ("162"), which reached Phase 1 trials in Australia but was terminated due to enrollment issues. The company is also involved in vaccines for COVID‑19 and HPV, with some assets approved or at NDA/BLA stage through collaborations. An oncolytic virus therapy targeting PD‑1 is being evaluated for CNS tumors/brain metastases in China at the Phase 1 stage[3][6][8]. Yangshengtang is a major Chinese private life sciences conglomerate founded by entrepreneur Zhong Shanshan. It operates primarily through subsidiaries such as Zhejiang Yangshengtang Biotechnology Co., Ltd. and especially Wantai BioPharm—a global leader in diagnostics and vaccines—with additional interests spanning pharma R&D into antibodies and oncolytic viruses.[5][6][7] Its pipeline covers infectious diseases like COVID–19, hepatitis E/B, HPV-related cancers/infections, plus early-stage oncology assets using innovative modalities such as monoclonal antibodies (“162”) and viral vectors (“rHSV‐APD1”). The company leverages strong academic partnerships within China while maintaining global ambitions through international trials and product distribution networks established by its subsidiaries.[2][3][6]